CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide
Dong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
Korean J Urol Oncol. 2021;19(1):60-69.   Published online 2021 February 26    DOI: https://doi.org/10.22465/kjuo.2021.19.1.60

Excel Download

Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide
Dong Hyeon An, Hwiwoo Kim, Donghyun Lee, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
The Korean Journal of Urological Oncology. 2021;19(1):60-69   Crossref logo
Link1 Link2 Link3
Enzalutamide for patients with metastatic castration-resistant prostate cancer
Wijdan Ramadan, Wissam Kabbara, Hiba Al Basiouni Al Masri
OncoTargets and Therapy. 2015;871   Crossref logo
Link1
Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Jeffrey Shevach, Bridget K. Marcellino, William K. Oh, Che-Kai Tsao
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. 2016;157-169   Crossref logo
Link1
232P Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
R. Raju, A. Sahu, M. Klevansky, J. Torres
Annals of Oncology. 2020;31:S1332   Crossref logo
Link1 Link2
Cost-Utility Analysis of Enzalutamide for Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (MCRPC)
C. Vicente, V. Babashov, F. Husein, F. Saad, S. Naidoo, S. Holmstrom
Value in Health. 2014;17(3):A89-A90   Crossref logo
Link1 Link2
Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study
Takeshi Azuma
The Prostate. 2018;78(4):278-278   Crossref logo
Link1 Link2
Predictive Models in Castration Resistant Prostate Cancer
Tao Cui, Michael W. Kattan
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. 2016;65-75   Crossref logo
Link1
Higher serum testosterone levels predict poor prognosis in castration‐resistant prostate cancer patients treated with docetaxel
Keisuke Ando, Shinichi Sakamoto, Nobushige Takeshita, Ayumi Fujimoto, Maihulan Maimaiti, Shinpei Saito, Pae Sanjyon, Yusuke Imamura, Nobuo Sato, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa
The Prostate. 2019;80(3):247-255   Crossref logo
Link1 Link2 Link3 Link4
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Mark Sanford
Drugs. 2013;73(15):1723-1732   Crossref logo
Link1 Link2 Link3
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis
Yupeng Guan, Haiyun Xiong, Yupeng Feng, Guolong Liao, Tongyu Tong, Jun Pang
Prostate Cancer and Prostatic Diseases. 2020;23(2):220-231   Crossref logo
Link1 Link2 Link3